Aurobindo Pharma gets USFDA’s nod for Rizatriptan Benzoate Tablets

01 Jan 2013 Evaluate

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Rizatriptan Benzoate Tablets 5mg (base) and 10mg (base) (ANDA 202490), which was earlier tentatively approved. The product is ready for launch.

Rizatriptan Benzoate Tablets 5mg (base) and 10mg (base) is the generic equivalent of Merck and Co’s Maxalt Tablets 5mg (base) and 10mg (base) and is indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old.

The annual sale of the product is approximately $300 million for the twelve months ending March 2012. The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, India Aurobindo now has a total of 171 ANDA approvals (146 Final approvals including 2 from Aurolife Pharma LLC and 25 tentative approvals) from USFDA

Aurobindo Pharma Share Price

1259.85 19.15 (1.54%)
23-Dec-2024 11:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1824.65
Dr. Reddys Lab 1350.40
Cipla 1486.20
Lupin 2185.55
Zydus Lifesciences 979.45
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.